Epigenetic modifiers are targeted in many therapeutic approaches for BCs, and our data provide pertinent evidence demonstrating that the efficacy of HDACIs in hormone-sensitive BC might involve repression of StAR expression with resultant decrease in E2 synthesis. Here, STAR is linked to breast cancer.